Clinical Trial Update: AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer [Phase 1, Phase 2]

View source ↗

Summary

This document reports the termination of a Phase 1/2 trial of AVB-S6-500 in combination with durvalumab for platinum-resistant or recurrent ovarian, fallopian t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• AVB-S6-500
• Durvalumab (durvalumab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2025-06-11